- Joined
- Jul 9, 2013
- Messages
- 5
- Reaction score
- 0
45 patient with hepatic metastases from non-pancreatic (npNET) or pancreatic (pNET) neuroendocrine tumor underwent TACE in this retrospective study. Median progression free survival (PFS) was 16.2 months and overall survival (OS) was 38.6 months for the whole group. Patients with npNET had similar PFS to patient with pNET (17.4 vs 15.3 months) but had longer OS (55.0 vs 25.6 months). Response rate was 58.1% (using RECIST 1.1 criteria). Enterobiliary communication, hepatic tumor burden and significant extrahepatic metastases before first chemoembolization were signficant risk factors for poor OS. The authors point out that the median OS corresponds with similar values on prior studies, although there is significant variability between those studies. Limitations include retrospective analysis, lack of consensus on how to measure tumor burden and lack of pathologic tumor grade given non-availability for every patient and recent changes to the grading system.